Home › Funds › Propel Bio Management, LLC › ABEO
Propel Bio Management, LLC position in ABEO
ABEONA THERAPEUTICS INC · Health Care
Propel Bio Management, LLC reported holding 956,007 shares of ABEO (ABEONA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 2.66% of its reported portfolio and ranking #12 among its reported holdings. Propel Bio Management, LLC has disclosed ABEO holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's ABEO position evolved
Propel Bio Management, LLC first disclosed a stake in ABEO in Q2 2024 at 1,248,044 shares (US$5.3M). The position peaked in Q2 2026 at 983,070 shares, worth US$6.1M. Across 10 filings, Propel Bio Management, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 956,007 shares valued at US$5.0M — a reduction of -27,063 shares quarter over quarter.. Notable position changes include a 50% trim in Q3 2024 (shares fell 12% over the following quarter), a 56% increase in Q2 2025 (shares fell 7% over the following quarter), a 60% increase in Q1 2026 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 1.25M | $5.29M | New |
| Q3 2024 | 624.02K | $3.94M | Reduce |
| Q4 2024 | 624.02K | $3.48M | Hold |
| Q1 2025 | 624.02K | $2.97M | Hold |
| Q2 2025 | 974.02K | $5.53M | Add |
| Q3 2025 | 974.02K | $5.14M | Hold |
| Q4 2025 | 830.78K | $4.38M | Reduce |
| Q1 2026 | 1.33M | $6.01M | Add |
| Q2 2026 | 983.07K | $6.08M | Reduce |
| Q3 2026 | 956.01K | $5.02M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABEO and 13F data
ABEO (ABEONA THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in ABEO — the largest reported positions include Cable Car Capital, LP (US$18.6M), AIGH Capital Management LLC (US$15.2M), AWM Investment Company, Inc. (US$9.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABEO
- Cable Car Capital, LP 3.01M sh · $18.59M · Q2 2026
- AIGH Capital Management LLC 2.90M sh · $15.22M · Q3 2026
- AWM Investment Company, Inc. 1.49M sh · $9.18M · Q2 2026
- Diametric Capital, LP 755.02K sh · $4.67M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 693.44K sh · $3.64M · Q3 2026
- Stonepine Capital Management, LLC 557.28K sh · $3.44M · Q2 2026
- Knoll Capital Management, LLC 485.51K sh · $3.00M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held ABEO?
Propel Bio Management, LLC has disclosed ABEO holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Propel Bio Management, LLC's current position in ABEO?
As of Q3 2026, Propel Bio Management, LLC holds 956.01K shares of ABEO (ABEONA THERAPEUTICS INC), valued at $5.02M, representing 2.66% of its reported portfolio and ranking #12.
Has Propel Bio Management, LLC been buying or selling ABEO?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in ABEO. The position peaked in Q2 2026 at 983.07K shares.
Which other funds hold ABEO?
Other major institutional holders of ABEO include Cable Car Capital, LP, AIGH Capital Management LLC, AWM Investment Company, Inc., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.